Generic Pharmaceuticals Contract Manufacturing Market to Surpass Valuation of US$ 135.43 Billion By 2033 | Astute Analytica [Yahoo! Finance]
Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)
Last teva pharmaceutical industries limited american depositary shares earnings: 2/13 04:01 pm
Check Earnings Report
US:NYSE Investor Relations:
ir.tevapharm.com
Company Research
Source: Yahoo! Finance
for biologics, and cost-effective healthcare solutions, with oncology and cardiovascular drugs leading the charge. New Delhi, Feb. 21, 2025 (GLOBE NEWSWIRE) -- The global generic pharmaceuticals contract manufacturing market is anticipated to be worth US$ 135.43 billion by 2033, growing at a CAGR of 6.15% during the forecast period 2025–2033. The generic pharmaceuticals contract manufacturing market is dominated by a mix of global giants and specialized players. Teva Pharmaceutical Industries, the second-largest generics manufacturer globally, generated $8.7 billion in revenue from generics in 2023, while Sandoz, the market leader, brought in $9.6 billion. These companies, along with others like Fresenius Kabi, Sun Pharmaceutic
Read more
Impact Snapshot
Event Time:
TEVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TEVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TEVA alerts
High impacting Teva Pharmaceutical Industries Limited American Depositary Shares news events
Weekly update
A roundup of the hottest topics
TEVA
News
- Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meetingGlobeNewswire
- Infertility Drugs Market to Reach USD 6.36 Billion by 2032 | Gonadotropins Segment Leads Growth, Online Pharmacies Emerging as Key Distribution Channel [Yahoo! Finance]Yahoo! Finance
- Here's Why Sound Shore Fund Added Teva Pharmaceutical Industries Limited (TEVA) in Q2 [Yahoo! Finance]Yahoo! Finance
- Teva's Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy [Yahoo! Finance]Yahoo! Finance
- Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System AtrophyGlobeNewswire
TEVA
Earnings
- 7/30/25 - Beat
TEVA
Analyst Actions
- 6/26/25 - UBS
TEVA
Sec Filings
- 9/12/25 - Form 144
- 9/9/25 - Form 4
- 8/6/25 - Form SCHEDULE
- TEVA's page on the SEC website